Sarah Cannon Research Institute: Advancing cancer care through innovative clinical trials

Sarah Cannon Research Institute (SCRI) is a world-leading clinical trials facility specialising in the development of new therapies and precision medication for cancer patients. We believe that participation in a clinical trial is the first step in fighting cancer, not the last.

As the research arm of HCA's global cancer institute, we are the first UK trials unit outside of the NHS that has the ability to offer new anti-cancer drugs in clinical trials. If you are eligible and choose to take part in one of our studies, you may receive innovative treatment and play an essential role in helping to improve cancer care for future patients. By bringing together the best medical minds with the most passionate caregivers, we are transforming care and personalising treatment.

Through clinical excellence and world-leading research, Sarah Cannon is redefining cancer treatment around the world.

Every trial is conducted by a principal investigator, who is an experienced oncologist, and is supported by a carefully selected research team. This team includes clinical research fellows and research nurses, who provide nursing care and act as your personal advocate throughout treatment.